Biomarkers As Approach in Variables of Therapeutic Potential

In the practice of medicine, biomarkers have become extremely valuable from a scientific and clinical standpoint. Biomarkers have the potential to be helpful at every stage of the disease process. Markers could be utilized for risk assessment and screening prior to diagnosis. Markers can be used to decide on initial therapy selection, staging, and grading during diagnosis. They can be used to track recurrent disorders, choose further therapies, or monitor therapy throughout treatment. Numerous prospective biomarkers with potential clinical utility have been produced by developments in molecular pathology, proteomics, and genomics. In order to accomplish “personalization” of therapy and illness prevention, biomarkers discovered through the use of new high-throughput technologies will need to be incorporated into medical practice.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-01-15
DOI
https://doi.org/10.5281/zenodo.14652014
Primary Topic
GDF15 and Related Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biomarkers As Approach in Variables of Therapeutic Potential

Zenodo (CERN European Organization for Nuclear Research)
GDF15 and Related Biomarkers
article

Biomarkers As Approach in Variables of Therapeutic Potential

article en

Abstract

In the practice of medicine, biomarkers have become extremely valuable from a scientific and clinical standpoint. Biomarkers have the potential to be helpful at every stage of the disease process. Markers could be utilized for risk assessment and screening prior to diagnosis. Markers can be used to decide on initial therapy selection, staging, and grading during diagnosis. They can be used to track recurrent disorders, choose further therapies, or monitor therapy throughout treatment. Numerous prospective biomarkers with potential clinical utility have been produced by developments in molecular pathology, proteomics, and genomics. In order to accomplish “personalization” of therapy and illness prevention, biomarkers discovered through the use of new high-throughput technologies will need to be incorporated into medical practice.

Zenodo (CERN European Organization for Nuclear Research)
Openalex Percentile: Top 40%
GDF15 and Related Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.